NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 44

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02126 3/55-85

Licensee

1. **Centerpoint Medical Center of Independence, LLC** (d/b/a Independence Regional Health Center)
2. 1509 W. Truman Road
   Independence, MO 64050

In accordance with letter dated **July 10, 2006,**

3. License number 24-18655-01 is amended in its entirety to read as follows:
4. Expiration date August 31, 2010
5. Docket No. 030-13994
   Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed
D. Any byproduct material permitted by 10 CFR 35.400	D. **Sealed Sources (IsoAid, L.L.C., Model IAI-125A, (Advantage ™ I-125), Medi-Physics, Inc., 6711 (OncoSeed ™), Theragenics Corporation, TheraSeed Model 200).**	D. **1 Curie total**
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources permitted by 10 CFR 35.500	E. 1 Curie total
F. Any byproduct material permitted by 10 CFR 31.11	F. Prepackaged Kits	F. **3 millicuries total**
G. Gadolinium-153	G. Sealed sources (North American Scientific, Inc. Model 3601)	G. 4 sources, not to exceed 300 millicuries each

9. Authorized Use:

   A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

   B. Any imaging and localization study permitted by 10 CFR 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-18655-01

Docket or Reference Number
030-13994

Amendment No. 44

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

E. For storage only incident to disposal.

F. In vitro studies.

G. Two sources to be used in Adac Laboratories Transmission Line Source Housing VANTAGE device for medical radiography in humans. Two sources in shipping containers for replacement of the sources.

CONDITIONS

10. Licensed material shall be used at the licensee's facilities located at 1509 W. Truman Road, Independence, Missouri and materials listed in Subitems 6.A, 6.B., and 6.C. (limited to hyperthyroid therapy) may be used at the licensee's facilities located at 19550 East 39th Street, Independence, Missouri.

11. The Radiation Safety Officer for this license is [redacted] Thompson, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users	Material and Use
David E. Hazuka, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.
Stephen R. Kunz, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500 , 31.11, and gadolinium-153 in VANTAGE device for medical radiography.
George William Pogson, M.D.	10 CFR 35.200 and gadolinium-153 in VANTAGE device for medical radiography.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-18655-01

Docket or Reference Number
030-13994

Amendment No. 44

Richard A. Morrison, M.D.	10 CFR 35.400 and 35.500.
Gwendolyn Ramsey Arnett, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.
Robert F. Thompson, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.
Richard L. Cronemeyer, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography
Paul Ren Chu, M.D.	10 CFR 35.200.
Stephen A. Bloom, M.D.	10 CFR 35.200 and gadolinium-153 in VANTAGE device for medical radiography.
James P. McGraw, M.D.	10 CFR 35.200 and gadolinium-153 in VANTAGE device for medical radiography.
Thomas L. Rosamond, M.D.	10 CFR 35.200 and gadolinium-153 in VANTAGE device for medical radiography.
Alan Schneider, M.D.	10 CFR 35.200 and gadolinium-153 in VANTAGE device for medical radiography.
Mark J. Lavin, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
William G. Jensen, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11 and gadolinium-153 in VANTAGE device for medical radiography.
Kenneth M. Alfieri, M.D.	10 CFR 35.100, 35.200, 35.300, 31.11 and gadolinium-153 in VANTAGE device for medical radiography.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-18655-01

Docket or Reference Number
030-13994

Amendment No. 44

Joseph J. Varriano, M.D.	10 CFR 35.100, 35.200, 35.300, 31.11 and gadolinium-153 in VANTAGE device for medical radiography.
Matthew R. Caterine, M.D.	10 CFR 35.100, 35.200, 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.
John M. Sheldon, M.D.	10 CFR 35.400.
Maynard C. Jones, M.D.	10 CFR 35.100 and 35.200, 35.300 (excluding thyroid carcinoma), 35.500 and 31.11.
Dipak Shah, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to iodine-131, strontium-89 and samarium-153), 35.500 and 31.11.
Michael J. Malis, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
David Mena, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
Michael N. Roys, M.D.	10 CFR 35.100, 35.200 and 31.11.

13. Notwithstanding the provisions of Section 35.[redacted] "Suppliers" of Title 10, Code of Federal Regulations, the licensee is authorized to receive 10 CFR Part 35.400 material from NRC License Number 24-19486-02 in accordance with Facsimile dated November 17, 2000.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

15. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

    B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

    C. Sealed sources need not be leak tested if are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-18655-01

Docket or Reference Number
030-13994

Amendment No. 44

D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

E. The licensee is authorized to collect leak test samples for analysis but not perform the analysis. Analysis of leak samples must be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

16. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

17. The licensee shall conduct a physical inventory every 3 months to account for all sources and/or devices received and possessed pursuant to 10 CFR 35.59, 10 CFR 35.400 and 10 CFR 35.500 and every 6 months for all other sources and/or devices.

18. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated July 21, 2000 (excluding ATT's 10.15 and 12.1);

B. Facsimile dated November 17, 2000 (excluding pages 7 and 8); and July 30, 2002; and

C. Letters dated April 15, 2002, March 26, 2003, April 15, 2003 (with enclosure) and February 13, 2006.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date OCT 0 5 2006

By William P Reichhold
William P. Reichhold
Materials Licensing Branch
Region III